A renaissance in marine pharmacology: From preclinical curiosity to clinical reality
A renaissance in marine pharmacology: From preclinical curiosity to clinical reality
复制标题
DOI：
10.1016/j.bcp.2009.04.015
复制
发表时间：
2009-09-01
影响因子：
5.8
通讯作者：
Mayer, Alejandro M. S.
中科院分区：
文献类型：
--
作者：
Glaser, Keith B.;Mayer, Alejandro M. S.
海洋药理学，即海洋天然产物的药理学，一段时间以来更多地与海洋天然产物化学联系在一起，而不是主要的药理学。然而，最近几年，这一研究领域出现了复兴，美国食品和药物管理局(FDA)于2004年批准Prialt(R)(zicbon，omega-conotoxx MVIIA)，这是一种在海洋蜗牛中发现的螺螺肽的合成等价物，用于治疗严重的慢性疼痛。此外，Yondelis(R)(trabectechn，ET-743)是在海洋殖民地被衣动物中发现的一种抗肿瘤药物，现在已合成生产，获得了欧盟委员会(EC)和FDA对软组织肉瘤和卵巢癌的孤儿药物称号，并于2007年在欧盟注册用于治疗软组织肉瘤。如此少的海洋天然产品的批准/营销是经过多年的研究，主要是由学术界和主要制药公司的零星参与。这篇评论将通过海洋天然产品领域的几位领导者提供的意见，审查学术界和医药界对开发海洋天然产品作为可行的治疗实体的潜在原因和看法。(C)2009 Elsevier Inc.保留所有权利。
Marine pharmacology, the pharmacology of marine natural products, has been for some time more associated with marine natural products chemistry rather than mainstay pharmacology. However, in recent years a renaissance has occurred in this area of research, and has seen the US Food & Drug Administration (FDA) approval in 2004 of Prialt(R) (ziconotide, omega-conotoxin MVIIA) the synthetic equivalent of a conopeptide found in marine snails, used for the management of severe chronic pain. Furthermore Yondelis(R) (trabectechn, ET-743) an antitumor agent discovered in a marine colonial tunicate, and now produced synthetically, receiving Orphan Drug designation from the European Commission (EC) and FDA for soft tissue sarcomas and ovarian cancer and its registration in 2007 in the EU for the treatment of soft tissue sarcoma. The approval/marketing of so few marine natural products has come after many years of research primarily by the academic community and the sporadic involvement: of major pharmaceutical companies. This commentary, through the opinions provided by several leaders in the marine natural products field, will examine the potential reasons and perceptions from both the academic and pharmaceutical communities regarding the development of marine natural products as viable therapeutic entities. (C) 2009 Elsevier Inc. All rights reserved.